一段没有路线图的旅程-需要验证 MS 前驱期的标准。
A journey with no roadmap-The need for validated criteria of the MS prodrome.
机构信息
The University of British Columbia, Vancouver, British Columbia, Canada.
出版信息
Mult Scler. 2023 Apr;29(4-5):502-504. doi: 10.1177/13524585221135883. Epub 2022 Nov 8.
BACKGROUND
A growing body of compelling evidence has emerged to validate a set of signs and symptoms that indicates the onset of disease before more typical signs and symptoms present to fulfill a diagnosis of MS. On 24 June 2021, a group of international researchers, patient advocates, and Society representatives led by Professors Helen Tremlett (University of British Columbia) and Ruth Ann Marrie (University of Manitoba) convened virtually for a workshop.
OBJECTIVE
Identify key gaps in knowledge, opportunities, and research priorities regarding the prodromal stage of MS.
METHODS
The group developed a new framework for MS that includes the stage of early signs and symptoms of MS-and outlined a roadmap to guide future research, with the "goal of preventing the progression to onset of typical symptoms of MS in those who present during the prodromal stage of MS".
RESULTS
If high-risk individuals in the early stages of MS can be identified with a high degree of certainty, there is an opportunity to intervene and minimize the risk of progressing to typical MS symptoms and a diagnosis of MS.
CONCLUSION
Standardized criteria must be developed, validated, and point of intervention found to better recognize, better diagnose, and better treat MS.
背景
越来越多的有力证据表明，在出现更典型的症状以满足多发性硬化症（MS）的诊断之前，有一组症状和体征可以预示疾病的发作。2021 年 6 月 24 日，由海伦·特雷莱特教授（英属哥伦比亚大学）和露丝·安·玛丽教授（马尼托巴大学）领导的一组国际研究人员、患者权益倡导者和学会代表在网上召开了一次研讨会。
目的
确定多发性硬化症前驱期的知识、机会和研究重点方面的主要差距。
方法
该小组为多发性硬化症制定了一个新的框架，包括多发性硬化症早期症状和体征阶段，并概述了指导未来研究的路线图，“目标是预防那些在多发性硬化症前驱期出现的患者向多发性硬化症典型症状和多发性硬化症诊断进展”。
结果
如果能够高度确定地识别多发性硬化症早期阶段的高危个体，那么就有机会进行干预，最大限度地降低进展为典型多发性硬化症症状和多发性硬化症诊断的风险。
结论
必须制定、验证和确定干预点的标准化标准，以更好地识别、诊断和治疗多发性硬化症。
Zotero 插件